Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 2—February 2012

Multiorgan Dysfunction Caused by Travel-associated African Trypanosomiasis

Lucy E. CottleComments to Author , Joanna R. Peters1, Alison Hall, J. Wendi Bailey, Harry A. Noyes, Jane E. Rimington, Nicholas J. Beeching, S. Bertel Squire, and Mike B.J. Beadsworth
Author affiliations: Royal Liverpool University Hospital, Liverpool, UK (L.E. Cottle, J.R. Peters, A. Hall, N.J. Beeching, S.B. Squire, M.B.J. Beadsworth); Liverpool School of Tropical Medicine, Liverpool (J.W. Bailey, N.J. Beeching, S.B. Squire, M.B.J. Beadsworth); University of Liverpool, Liverpool (H.A. Noyes); Hawkshead Medical Practice, Ambleside, UK (J.E. Rimington)

Main Article

Table 1

Treatment regimen for Trypanosoma brucei rhodesiense infection in adults*

Disease stage Drug, route of administration Regimen Adverse effects
First Suramin, intravenous Test dose of 100 mg in 100 mL 0.9% saline over 30 min on day 0; and 5 doses of 20 mg/kg (maximum 1 g/dose) in 250 mL 0.9% saline over 3 h on days 1, 3, 7, 14, 21 Hypersensitivity reactions (early and late); nephrotoxicity, hepatotoxicity, hemolytic anemia, peripheral neuropathy, agranulocytosis, thrombocytopenia, and cutaneous reactions
Second Melarsoprol, intravenous 2.0–3.6 mg/kg/d (maximum 180 mg/d) for 3 d; after 7 d, 3.6 mg/kg/d for 3 d; after 7 more d, 3.6 mg/kg/d for 3 d† Encephalopathy, cutaneous reactions, peripheral neuropathy, cardiac arrhythmias, thrombophlebitis, fever, and gastric upset

*Source of drug regimen: Brun et al. (2) and Abramowicz (3).
†In frail patients, begin with 18 mg melarsoprol and progressively increase dose (3). Pretreatment with suramin for 2–4 d is recommended for debilitated patients.

Main Article

  1. Welburn  SC, Picozzi  K, Fèvre  EM, Coleman  PG, Odiit  M, Carrington  M, Identification of human-infective trypanosomes in animal reservoir of sleeping sickness in Uganda by means of serum-resistance-associated (SRA) gene. Lancet. 2001;358:20179. DOIPubMedGoogle Scholar
  2. Brun  R, Blum  J, Chappuis  F, Burri  C. Human African trypanosomiasis. Lancet. 2010;375:14859. DOIPubMedGoogle Scholar
  3. Abramowicz  M. Drugs for parasitic infections. In: Abramowicz M, editor. The medical letter on drugs and therapeutics. New Rochelle (NY): The Medical Letter, Inc; 2000. p. 1–12.
  4. Kennedy  PG. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol. 2008;64:11626. DOIPubMedGoogle Scholar
  5. Gautret  P, Clerinx  J, Caumes  E, Simon  F, Jensenius  M, Loutan  L, Imported human African trypanosomiasis in Europe, 2005–2009. Euro Surveill. 2009;14:pii:19327. PubMedGoogle Scholar
  6. ProMED-mail. Archive nos. 20100915.3338, 20101022.3833, and 20101111.4093 [cited 2011 Sep 22].
  7. Sinha  A, Grace  C, Alston  WK, Westenfeld  F, Maguire  JH. African trypanosomiasis in two travelers from the United States. Clin Infect Dis. 1999;29:8404. DOIPubMedGoogle Scholar
  8. Reincke  M, Arlt  W, Heppner  C, Petzke  F, Chrousos  GP, Allolio  B. Neuroendocrine dysfunction in African trypanosomiasis. Ann N Y Acad Sci. 1998;840:80921. DOIPubMedGoogle Scholar
  9. Burri  C. Chemotherapy against human African trypanosomiasis: is there a road to success? Parasitology. 2010;137:198794. DOIPubMedGoogle Scholar
  10. Rodgers  J. Human African trypanosomiasis, chemotherapy and CNS disease. J Neuroimmunol. 2009;211:1622. DOIPubMedGoogle Scholar
  11. World Health Organization. Control and surveillance of African trypanosomiasis. Report of a WHO expert committee. WHO Technical Report Series. 1998;881:I–VI, 1–114.
  12. Vanhamme  L, Paturiaux-Hanocq  F, Poelvoorde  P, Nolan  DP, Lins  L, Van Den Abbeele  J, Apolipoprotein L–I is the trypanosome lytic factor of human serum. Nature. 2003;422:837. DOIPubMedGoogle Scholar
  13. Pays  E, Vanhollebeke  B. Human innate immunity against African trypanosomes. Curr Opin Immunol. 2009;21:4938. DOIPubMedGoogle Scholar
  14. Vanhollebeke  B, Truc  P, Poelvoorde  P, Pays  A, Joshi  PP, Katti  R, Human Trypanosoma evansi infection linked to a lack of apolipoprotein L–I. N Engl J Med. 2006;355:27526. DOIPubMedGoogle Scholar

Main Article

1Current affiliation: Worthing Hospital, Worthing, UK.

Page created: January 24, 2012
Page updated: January 24, 2012
Page reviewed: January 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.